Keynote speaker video from virtual HD Therapeutics Conference 2021 now available online

Keynote speakers, almost always from an HD family, open each year’s HD Therapeutics Conference with their own unique story to remind the scientists why they are gathered. At the 2021 conference held online April 27-29, we caught up with each of the Keynote speakers from the previous 15 years to learn how their very personal presentations had affected them both then and now, and to hear their own impressions of how HD drug development has progressed.

Read more…

Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease

LONDON–(BUSINESS WIRE)–Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington’s disease (HD). The grant will support Alchemab in its pioneering collaboration with Medicines Discovery Catapult. Read more…